 It is proposed to treat high-risk colorectal patients Stage IIIC T4a, N2a, M0 or T3-4a,N2b, M0, or T4b, N1-N2, M0 per American Joint Committee on Cancer AJCC 7th ed. selected from the iKnowMed iKM electronic health records database who have completed adjuvant FOLFOX. This feasibility study is to find the starting dose of regorafenib and estimates that at least 75 of the patients will be able to tolerate the full dose of regorafenib after receiving adjuvant FOLFOX. 